Evidence map›Paper›PMID 40662849›Full record

ArticleOncoimmunology2025

An immunological mechanism of resistance to CDK4/6 inhibitors in HR

Claudia Galassi, Giulia Petroni, Simon R V Knott, Lorenzo Galluzzi

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Claudia GalassiDepartment of Pharmacology, Weill Cornell Medical College, New York, NY, USA.
Giulia PetroniDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Simon R V KnottDepartment of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0002-4018-7653
Lorenzo GalluzziCancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.ORCID 0000-0003-2257-8500

Funding

Radiation Effect on Immune Cells and the MicrobiomeU54CA274291 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI John Ng · 2022 to 2026
$9.1M
Targeting the BCL2 immune checkpoint to enhance the immunostimulatory effects of radiation in breast cancerR01CA271915 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Lorenzo Galluzzi · 2023 to 2026
$2.9M
NCI NIH HHS R01 CA271915NCI NIH HHS U54 CA274291US DoD BCRP #BC180476P1US DoD BCRP #BC210945US DoD BCRP #W81XWH2120034
6 · The paper itself

Abstract

CDK4/6 inhibitors are central to the clinical management of HR

Indexed as

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Drug Resistance, NeoplasmProtein Kinase InhibitorsAnimalsErb-b2 Receptor Tyrosine KinasesFemaleHumansIntraepithelial LymphocytesReceptors, EstrogenTumor-Associated MacrophagesTumor MicroenvironmentCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Erb-b2 Receptor Tyrosine KinasesProtein Kinase InhibitorsReceptors, EstrogenCirculating biomarkerendocrine therapyhypoxiapalbociclibsingle-cell RNA sequencingTAMs

Identifiers

PMID40662849
PMCPMC12269697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.